Sierra Summit Advisors LLC Makes New $844,000 Investment in Halozyme Therapeutics, Inc. $HALO

Sierra Summit Advisors LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 12,538 shares of the biopharmaceutical company’s stock, valued at approximately $844,000.

Several other institutional investors have also modified their holdings of HALO. Empowered Funds LLC bought a new stake in shares of Halozyme Therapeutics in the 1st quarter valued at approximately $755,000. Acadian Asset Management LLC bought a new stake in shares of Halozyme Therapeutics in the 1st quarter valued at approximately $195,000. Hsbc Holdings PLC lifted its stake in shares of Halozyme Therapeutics by 117.1% in the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock valued at $522,000 after purchasing an additional 5,448 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Halozyme Therapeutics by 6.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 174 shares during the last quarter. Finally, Baird Financial Group Inc. lifted its stake in shares of Halozyme Therapeutics by 6.2% in the 2nd quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock valued at $577,000 after purchasing an additional 650 shares during the last quarter. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Price Performance

Shares of HALO stock opened at $68.52 on Friday. Halozyme Therapeutics, Inc. has a 52-week low of $51.06 and a 52-week high of $82.22. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. The firm has a market capitalization of $8.13 billion, a P/E ratio of 24.65, a P/E/G ratio of 0.28 and a beta of 0.89. The stock has a 50 day moving average price of $65.70 and a 200 day moving average price of $68.75.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company had revenue of $376.71 million during the quarter, compared to analyst estimates of $358.60 million. During the same quarter last year, the business posted $1.11 EPS. The firm’s revenue for the quarter was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 7.66 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. HC Wainwright raised their target price on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Wells Fargo & Company raised their target price on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a report on Thursday, February 19th. TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. Finally, Morgan Stanley lowered their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Seven equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $80.67.

Insider Activity at Halozyme Therapeutics

In related news, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $69.19, for a total transaction of $691,900.00. Following the completion of the sale, the chief executive officer owned 767,780 shares in the company, valued at $53,122,698.20. This trade represents a 1.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 8,857 shares of Halozyme Therapeutics stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $67.64, for a total transaction of $599,087.48. Following the sale, the chief operating officer owned 7,055 shares of the company’s stock, valued at $477,200.20. The trade was a 55.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 120,482 shares of company stock worth $8,200,842 in the last 90 days. 2.50% of the stock is owned by corporate insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.